The role of naftopidil in the management of benign prostatic hyperplasia
Naftopidil, which to a certain extent shows an affinity to α 1D -adrenoceptor subtype in addition to a high affinity to α 1A -adrenoceptor, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The aim o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-04-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287212461681 |